Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis.


Journal

Radiation research
ISSN: 1938-5404
Titre abrégé: Radiat Res
Pays: United States
ID NLM: 0401245

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 16 8 2019
medline: 6 2 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

Radiation therapy is a mainstream strategy in the treatment of several cancer types that are surgically unresectable. Unfortunately, cancer patients often suffer from unintended consequences of radiotherapy, including the development of skin inflammation (dermatitis), which may progress to fibrosis. These morbid complications often require interruption of radiotherapy and threaten the relapse of underlying cancer. Current treatment options for radiation dermatitis are suboptimal and compel the need to develop safer, more effective therapies. In this study, we assessed the biophysical properties of topically-formulated esomeprazole (here referred to as dermaprazole) and performed proof-of-concept studies to evaluate its efficacy

Identifiants

pubmed: 31415221
pii: 10.1667/RR15398.1
doi: 10.1667/RR15398.1
pmc: PMC6876297
mid: NIHMS1059282
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Membrane Proteins 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Nfe2l2 protein, mouse 0
HMOX1 protein, human EC 1.14.14.18
Heme Oxygenase-1 EC 1.14.14.18
Hmox1 protein, mouse EC 1.14.14.18
Esomeprazole N3PA6559FT

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

473-482

Subventions

Organisme : NICHD NIH HHS
ID : P01 HD087157
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE026682
Pays : United States
Organisme : BLRD VA
ID : IK2 BX004183
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137703
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL118683
Pays : United States
Organisme : FDA HHS
ID : R01 FD005109
Pays : United States

Références

Curr Med Chem. 2009;16(2):130-43
pubmed: 19149566
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
pubmed: 10758303
Jpn J Clin Oncol. 2000 May;30(5):230-4
pubmed: 10857501
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Clin Oncol (R Coll Radiol). 2013 Oct;25(10):578-85
pubmed: 23849504
Am J Clin Oncol. 2009 Dec;32(6):587-91
pubmed: 19581794
Curr Pharm Des. 2010;16(4):411-20
pubmed: 20236069
Radiat Res. 2014 May;181(5):512-20
pubmed: 24720753
Front Pharmacol. 2017 Jan 26;8:16
pubmed: 28184197
Clin Oncol (R Coll Radiol). 1997;9(5):282-93
pubmed: 9368723
Arch Dermatol Res. 2003 Dec;295(7):293-6
pubmed: 14615895
Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:74-81
pubmed: 10807407
Adv Skin Wound Care. 2002 Sep-Oct;15(5):216-24
pubmed: 12368711
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13
pubmed: 15547183
Am J Respir Cell Mol Biol. 1996 Jul;15(1):9-19
pubmed: 8679227
Circulation. 2013 Aug 20;128(8):845-53
pubmed: 23825361
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):99-109
pubmed: 7642437
Inflamm Res. 2006 Nov;55(11):476-80
pubmed: 17122965
BMC Cancer. 2014 Jan 31;14:53
pubmed: 24484999
Radiat Oncol. 2012 Jan 17;7:4
pubmed: 22247972
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Oncologist. 2010;15(4):350-9
pubmed: 20413640
Clin Cosmet Investig Dermatol. 2016 Dec 09;9:473-482
pubmed: 28003769
Cancer Prev Res (Phila). 2014 Dec;7(12):1258-69
pubmed: 25468899
J Transl Med. 2015 Aug 01;13:249
pubmed: 26231702
J Clin Invest. 2013 Dec;123(12):5361-70
pubmed: 24231355
Radiat Oncol. 2012 Dec 08;7:208
pubmed: 23216952
J Pathol. 2014 Feb;232(3):289-99
pubmed: 24254983
Cardiol Res Pract. 2012;2012:521958
pubmed: 22111028
Biochem Pharmacol. 2006 Apr 28;71(9):1337-41
pubmed: 16494850
J BUON. 2010 Jul-Sep;15(3):577-82
pubmed: 20941831
J Biol Chem. 2003 Mar 28;278(13):10993-1001
pubmed: 12529378
Sci Transl Med. 2011 Jun 15;3(87):87ra53
pubmed: 21677199
J Radiat Res. 2016 Sep;57(5):567-571
pubmed: 27242339
J Invest Dermatol. 1996 Dec;107(6):815-21
pubmed: 8941667

Auteurs

Ngoc Pham (N)

Departments of Radiation Oncology.

Michelle S Ludwig (MS)

Departments of Radiation Oncology.

Min Wang (M)

Departments of Radiation Oncology.

Afshin Ebrahimpour (A)

Departments of Radiation Oncology.

Mark D Bonnen (MD)

Departments of Radiation Oncology.

Abdul Hafeez Diwan (AH)

Departments of Pathology and Immunology.

Soo Jung Kim (SJ)

Departments of Dermatology.

Jason Bryan (J)

Departments of Smith Radiation Oncology Clinic, Harris Health System, Houston, Texas 77030.

Jared M Newton (JM)

Departments of Otolaryngology - Head and Neck Surgery.
Departments of Interdepartmental Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas 77030.

Andrew G Sikora (AG)

Departments of Otolaryngology - Head and Neck Surgery.

Donald T Donovan (DT)

Departments of Otolaryngology - Head and Neck Surgery.

Vlad Sandulache (V)

Departments of Otolaryngology - Head and Neck Surgery.

Yohannes T Ghebre (YT)

Departments of Radiation Oncology.
Departments of Medicine, Section on Pulmonary and Critical Care Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH